Article
Telithromycin. Fresh from the Pipeline
Nature Reviews Drug Discovery
Document Type
Article
Publication Date
9-1-2004
Disciplines
Abstract
In April 2004, telithromycin (Ketek; Aventis), the first of a new class of antibacterial drugs derived from macrolides, was approved by the US FDA for the treatment of several respiratory-tract infections. After a delay in its approval owing to a need to address potential safety issues, is it likely to now attain the blockbuster status that had originally been widely predicted?
Citation Information
Aarti Raja, J. Lebbos and P. Kirtpatrick. "Telithromycin. Fresh from the Pipeline" Nature Reviews Drug Discovery (2004) ISSN: 1474-1776 Available at: http://works.bepress.com/aarti-raja/9/